{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:30:02Z","timestamp":1786242602285,"version":"build-2736575974"},"reference-count":47,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clinical Cancer Informatics"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p> This work summarizes the benefit and risk of the results of clinical trials submitted to the US Food and Drug Administration of therapies for the treatment of non\u2013small cell lung cancer (NSCLC) using number needed to benefit (NNB) and number needed to harm (NNH) metrics. NNB and NNH metrics have been reported as potentially being more patient centric and more intuitive to medical practitioners than more common metrics, such as the hazard ratio, and valuable to medical practitioners in complementing other metrics, such as the median time to event. This approach involved the characterization of efficacy and safety results in terms of NNB and NNH of 30 clinical trials in advanced NSCLC supporting US Food and Drug Administration approval decisions from 2003 to 2017. We assessed trends of NNB over time of treatment (eg, for programmed death 1 inhibitors) and variation of NNB across subpopulations (eg, characterized by epidermal growth factor receptor mutation, programmed death ligand 1 expression, Eastern Cooperative Oncology Group performance status, age, and extent of disease progression). Furthermore, the evolution of NNB of treatments for advanced NSCLC was charted from 2003 to 2017. Across subpopulations, NNB, on average, was 4 patients for approved targeted therapies in molecularly enriched populations, 11 patients for approved therapies in nonmolecularly enriched populations, and 23 patients for withdrawn or unapproved therapies. Furthermore, the NNB analysis showed variation for attributes of epidermal growth factor receptor mutations, level of programmed death 1 expression, Eastern Cooperative Oncology Group performance status, etc. When considering the best-case subpopulations and available drugs, the NNB frontier reduced from an estimated value of 7.7 in 2003 to an estimated value of 2.5 in 2017 at the estimated median overall survival\u2014equal to 6 months\u2014of an untreated patient. <\/jats:p>","DOI":"10.1200\/cci.19.00103","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T19:57:29Z","timestamp":1598558249000},"page":"769-783","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Patient-Centered Approach to Benefit\u2013Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1200","author":[{"given":"Gokaraju K.","family":"Raju","sequence":"first","affiliation":[{"name":"Light Pharma, Cambridge, MA"},{"name":"Massachusetts Institute of Technology, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Khozin","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Gurumurthi","sequence":"additional","affiliation":[{"name":"Light Pharma, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Domike","sequence":"additional","affiliation":[{"name":"Light Pharma, Cambridge, MA"},{"name":"Brigham Young University, Provo, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Woodcock","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60569-9"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu349.52"},{"key":"B6","volume-title":"Benefit-Risk Framework","author":"Frey P","year":"2012"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.93"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.88"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6977.452"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182605"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7223.1492"},{"key":"B13","first-page":"1000334","volume":"6","author":"Pettitt D. A.","year":"2016","journal-title":"J Stem Cell Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.507"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.501"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.871"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1461"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61758-4"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.721"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2266"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61497-5"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0101"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00006-6"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0498"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0642"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.09.015"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5190"},{"key":"B54","first-page":"54","volume":"23","author":"Karweit J","year":"2017","journal-title":"Am J Manag Care"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S177343"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31814617a2"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq742"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2361"},{"key":"B59","volume-title":"Survival Analysis","author":"Miller RG","year":"1998","edition":"2"},{"key":"B60","first-page":"263","volume":"70","author":"Ku HH","year":"1966","journal-title":"J Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7168.1309"},{"key":"B62","volume-title":"Statistics for Experimenters","author":"Box GEP","year":"1978"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.5772"}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI.19.00103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:18:23Z","timestamp":1653812303000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI.19.00103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1200\/CCI.19.00103"],"URL":"https:\/\/doi.org\/10.1200\/cci.19.00103","relation":{},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}